Foghorn Therapeutics (FHTX)
NASDAQ:FHTX
FHTX Stock Chart & Stats
$4.59
$0.09(1.92%)
At close: 4:00 PM EST
$4.59
$0.09(1.92%)
Day’s Range― - ―
52-Week Range$3.26 - $6.95
Previous CloseN/A
Volume24.60K
Average Volume (3M)157.41K
Market Cap
$269.43M
Enterprise Value$235.70M
Total Cash (Recent Filing)$158.89M
Total Debt (Recent Filing)$41.27M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
May 11, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding58,700,245
10 Day Avg. Volume207,613
30 Day Avg. Volume157,412
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)-3.13
Price to Sales (P/S)11.00
P/FCF Ratio-3.95
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue7.63
Enterprise Value/Gross Profit25.61
Enterprise Value/Ebitda-3.23
Forecast
1Y Price Target
$11.67Price Target Upside154.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.11
Revenue Forecast (FY)$35.70M
Bulls Say, Bears Say
Bulls Say
Clinical Safety And Dose EscalationAnalyst notes that FHD-909's Phase 1a dose-escalation has not identified a maximum tolerated dose, suggesting a favorable safety profile that could allow stronger target coverage and more durable responses in lung cancer patients.
Preclinical Pipeline ExpansionAnalyst highlights that wholly owned CBP and EP300 degrader programs moving toward IND-enabling studies, alongside an ARID1B candidate progressing to in vivo proof of concept, broadens the company's pipeline and potential future value beyond the partnered SMARCA2 asset.
Strategic Partnership And Development DecisionAnalyst observes that an active collaboration with a major pharmaceutical partner and rising clinical site activity increase the likelihood of advancing FHD-909 into dose-expansion cohorts, which could validate the asset and attract additional development resources.
Bears Say
Patient Population And Clinical Outcome RiskAnalyst cautions that the target patient population is heavily pretreated and biologically aggressive, which increases the difficulty of demonstrating meaningful clinical responses and creates a pivotal clinical outcome risk for company valuation.
Program History And Funding RiskAnalyst notes that prior discontinuation of FHD-286 after failing internal response benchmarks creates uncertainty about restarting development and could require additional funding that raises the risk of shareholder dilution.
Revenue And Near-term FinancialsAnalyst points out that reported collaboration revenue fell short of expectations, signaling near-term weakness in partnership income and potential downside pressure on financial forecasts.
Foghorn Therapeutics News
FHTX FAQ
What was Foghorn Therapeutics’s price range in the past 12 months?
Foghorn Therapeutics lowest stock price was $3.26 and its highest was $6.95 in the past 12 months.
What is Foghorn Therapeutics’s market cap?
Foghorn Therapeutics’s market cap is $269.43M.
When is Foghorn Therapeutics’s upcoming earnings report date?
Foghorn Therapeutics’s upcoming earnings report date is May 11, 2026 which is in 27 days.
How were Foghorn Therapeutics’s earnings last quarter?
Foghorn Therapeutics released its earnings results on Mar 11, 2026. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.264 by -$0.086.
Is Foghorn Therapeutics overvalued?
According to Wall Street analysts Foghorn Therapeutics’s price is currently Undervalued.
Does Foghorn Therapeutics pay dividends?
Foghorn Therapeutics does not currently pay dividends.
What is Foghorn Therapeutics’s EPS estimate?
Foghorn Therapeutics’s EPS estimate is -0.31.
How many shares outstanding does Foghorn Therapeutics have?
Foghorn Therapeutics has 58,700,245 shares outstanding.
What happened to Foghorn Therapeutics’s price movement after its last earnings report?
Foghorn Therapeutics reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.264. Following the earnings report the stock price went down -12.92%.
Which hedge fund is a major shareholder of Foghorn Therapeutics?
Currently, no hedge funds are holding shares in FHTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Foghorn Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.67 (154.25% Upside)
$11.67 (154.25% Upside)
Hedge Fund Trend
Increased
By 306.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 3.2%
Last 30 Days ▲ 3.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.32%
12-Months-Change
Fundamentals
Return on Equity
105.48%
Trailing 12-Months
Asset Growth
-33.53%
Trailing 12-Months
Company Description
Foghorn Therapeutics
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
FHTX Stock 12 Month Forecast
Average Price Target
$11.67
▲(154.25% Upside)
Technical Analysis
Ownership Overview
1.10% Insiders
9.16% Mutual Funds
42.81% Other Institutional Investors
41.60% Public Companies and
Individual Investors